MX2013004588A - Derivados de triazol y su uso para trastornos neurologicos. - Google Patents

Derivados de triazol y su uso para trastornos neurologicos.

Info

Publication number
MX2013004588A
MX2013004588A MX2013004588A MX2013004588A MX2013004588A MX 2013004588 A MX2013004588 A MX 2013004588A MX 2013004588 A MX2013004588 A MX 2013004588A MX 2013004588 A MX2013004588 A MX 2013004588A MX 2013004588 A MX2013004588 A MX 2013004588A
Authority
MX
Mexico
Prior art keywords
sup
neurological disorders
triazole derivatives
present
compounds
Prior art date
Application number
MX2013004588A
Other languages
English (en)
Other versions
MX347706B (es
Inventor
Andrew Thomas
Matthew C Lucas
Maria-Clemencia Hernandez
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013004588A publication Critical patent/MX2013004588A/es
Publication of MX347706B publication Critical patent/MX347706B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención está relacionada con nuevos compuestos de triazol de la fórmula (I) en donde A, X, Y, Z, R1, R2 y R3 son como se describen aquí, así como a las sales y ésteres de los mismos farmacéuticamente aceptables. Los compuestos activos de la presente invención tienen afinidad y selectividad hacia el receptor GABA A a5. Además, la presente invención está relacionada con la manufactura de los compuestos de la fórmula (I), con las composiciones farmacéuticas que los comprenden y con su uso como medicamentos.
MX2013004588A 2010-11-09 2011-11-07 Derivados de triazol y su uso para trastornos neurologicos. MX347706B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10190415 2010-11-09
PCT/EP2011/069496 WO2012062687A1 (en) 2010-11-09 2011-11-07 Triazole derivatives and their use for neurological disorders

Publications (2)

Publication Number Publication Date
MX2013004588A true MX2013004588A (es) 2013-05-17
MX347706B MX347706B (es) 2017-05-09

Family

ID=44906177

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004588A MX347706B (es) 2010-11-09 2011-11-07 Derivados de triazol y su uso para trastornos neurologicos.

Country Status (12)

Country Link
US (1) US8742097B2 (es)
EP (1) EP2638029B1 (es)
JP (1) JP5918774B2 (es)
KR (1) KR20130115294A (es)
CN (1) CN103221402B (es)
BR (1) BR112013011610A2 (es)
CA (1) CA2812667A1 (es)
ES (1) ES2523892T3 (es)
HK (1) HK1182704A1 (es)
MX (1) MX347706B (es)
RU (1) RU2581504C2 (es)
WO (1) WO2012062687A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
US9475797B2 (en) 2012-06-26 2016-10-25 Saniona A/S Phenyl triazole derivative and its use for modulating the GABAA receptor complex
CN104411699B (zh) * 2012-06-26 2017-06-13 萨尼奥纳有限责任公司 苯基三唑衍生物及其用于调节gabaa 受体复合体的用途
JP6728198B2 (ja) 2015-01-30 2020-07-22 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 置換トリアゾールおよびそれに関する方法
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
TWI830713B (zh) 2017-12-19 2024-02-01 美商必治妥美雅史谷比公司 作為lpa拮抗劑之三唑n-連接之胺甲醯基環己基酸
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
EP3830093A1 (en) 2018-07-27 2021-06-09 Biotheryx, Inc. Bifunctional compounds as cdk modulators
HU231223B1 (hu) * 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
TW202202495A (zh) 2020-03-26 2022-01-16 匈牙利商羅特格登公司 作為ｇａｍｍａ－胺基丁酸Ａ受體次單元ａｌｐｈａ ５受體調節劑之㖠啶及吡啶并〔３，４－ｃ〕嗒𠯤衍生物
US20240043418A1 (en) 2020-03-26 2024-02-08 Richter Gedeon Nyrt. 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CN115461337A (zh) 2020-05-13 2022-12-09 豪夫迈·罗氏有限公司 作为GABA A α5 PAM的新型三唑基衍生物
EP4192823A1 (en) 2020-08-05 2023-06-14 Boehringer Ingelheim International GmbH Difluoromethyl-pyridin-2-yl triazoles
EP3992188A1 (en) * 2020-10-29 2022-05-04 Boehringer Ingelheim International GmbH Difluoromethyl-pyridin-2-yl triazoles
AU2022270411A1 (en) 2021-05-05 2023-11-23 University College Cardiff Consultants Limited Heteroaryl compounds useful in the treatment of cognitive disorders
HUP2100338A1 (hu) 2021-09-29 2023-04-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN114656473B (zh) * 2022-04-27 2023-09-29 成都施贝康生物医药科技有限公司 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656472B (zh) * 2022-04-27 2023-07-04 成都施贝康生物医药科技有限公司 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237793B (it) 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
TW200533346A (en) * 2004-03-18 2005-10-16 Hoffmann La Roche Novel ether derivatives, their manufacture and use as pharmaceutical agents
ATE460403T1 (de) * 2006-05-24 2010-03-15 Lilly Co Eli Verbindungen und verfahren zur modulierung von fx-rezeptoren
JP2011515359A (ja) * 2008-03-18 2011-05-19 グラクソ グループ リミテッド 治療用トリアゾールアミド誘導体
TWI378096B (en) 2008-06-19 2012-12-01 Takeda Pharmaceutical Heterocyclic compound and use thereof

Also Published As

Publication number Publication date
EP2638029B1 (en) 2014-09-24
CN103221402A (zh) 2013-07-24
CA2812667A1 (en) 2012-05-18
WO2012062687A1 (en) 2012-05-18
EP2638029A1 (en) 2013-09-18
US8742097B2 (en) 2014-06-03
ES2523892T3 (es) 2014-12-02
US20120115844A1 (en) 2012-05-10
BR112013011610A2 (pt) 2016-08-09
HK1182704A1 (en) 2013-12-06
RU2581504C2 (ru) 2016-04-20
JP2013543852A (ja) 2013-12-09
KR20130115294A (ko) 2013-10-21
JP5918774B2 (ja) 2016-05-18
MX347706B (es) 2017-05-09
CN103221402B (zh) 2015-06-17
RU2013125337A (ru) 2014-12-20

Similar Documents

Publication Publication Date Title
MX2013004588A (es) Derivados de triazol y su uso para trastornos neurologicos.
MX2011007772A (es) Derivados de isoxazol/o-piridina con enlazador etilo y etenilo.
MX2011011484A (es) Derivados de isoxazol-piridina como moduladores del acido gamma-aminobutirico.
MX2011007737A (es) Derivados de hidroximetil isoxazol como moduladores de acido gamma-aminobutirico a.
MY158974A (en) Prodrugs comprising an exendin linker conjugate
MX2012001399A (es) Profarmacos que comprenden un conjugado de insulina-conector.
MX2011011489A (es) Derivados de isoxazol-piridina.
MX2011007774A (es) Derivados de isoxazol-isoxazol e isoxazol-isotiazol.
TN2012000125A1 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
MX2011011303A (es) Derivados de isoxazol.
TW200728307A (en) Novel spirochromanone derivatives
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2012122340A8 (en) Soluble guanylate cyclase activators
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
MX2011011273A (es) Derivados de isoxazol-pirazol.
MX2013001929A (es) Nuevos compuestos
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
MX2010004232A (es) Compuesto de indolina de pirimidilo.
MX2011011477A (es) Derivados de isoxazol-piridazina.
WO2012048129A3 (en) Inhibitors of polo-like kinase
MX2013000474A (es) Derivados de arilamida novedosos que tienen propiedades antiandrogenicas.
MY187718A (en) Pharmaceutical formulations
WO2012054721A8 (en) Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
MX345544B (es) Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba).
MX2009014001A (es) Derivados de isoxazol-imidazol.

Legal Events

Date Code Title Description
FG Grant or registration